Lysosomal Alpha Glucosidase Market 2021 Growth, COVID Impact, Trends Analysis Report 2027
The global lysosomal alpha glucosidase market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Lysosomal alpha glucosidase is termed as a recombinant enzyme used to treat lysosomal storage disorder known as Pompe disease (which is also known by the name acid maltase deficiency or glycogen storage disease type II). Pompe disease is perceived as an inherited fatal muscular myopathy disorder caused due to the glycogen build-up in the body cells such as in cardiac, smooth, and skeletal muscle cells. The disease is further characterized by the absence and in some cases, deficiency of the lysosomal enzyme alpha-glucosidase. The market growth is majorly driven by the growing research coupled with the increasing clinical trials that ensures a robust product pipeline for the future years.
To Request a Sample of our Report on Lysosomal Alpha
Glucosidase Market: https://www.omrglobal.com/request-sample/lysosomal-alpha-glucosidase-market
Key players such as Sanofi have already initiated the
clinical trials which spurred the market growth. For instance, in 2016, in
order to treat Pompe disease, Genzyme, a unit of Sanofi, started phase III
clinical trial for NeoGAA, a second generation alglucosidase alfa enzyme-based
enzyme replacement therapy. Further, in 2017, Valerion Therapeutic, a
clinical-stage biotechnology company specialized in the development of
therapies for orphan genetic diseases, initiated phase I/II clinical trials for
its candidate drug, VAL-1221 in patients with late-onset of Pompe disease.
VAL-1221 combines company’s proprietary antibody-mediated delivery technology
with recombinant human acid alpha-glucosidase, offering improved glycogen
clearance and better patient outcomes. In February 2018, a biotechnology
company named Audentes Therapeutics, Inc. conducted phase I/II clinical trial
for AT982 for commercializing and developing gene therapy products to treat
Pompe disease.
Market Coverage
•
The market number available for – 2020-2027
•
Base year- 2020
•
Forecast period- 2021-2027
Segment Covered-
·
By Product
·
By Distribution Channel
Regions covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
Competitive Landscape:
Amicus Therapeutics Inc., and Sanofi SA, among others.
(Get 15% Discount on Buying this Report)
A
full Report of Lysosomal Alpha Glucosidase Market is Available @ https://www.omrglobal.com/industry-reports/lysosomal-alpha-glucosidase-market
Global Lysosomal Alpha Glucosidase Market Report by
Segment
By Product
• Myozyme
• Lumizyme
By Distribution Channel
• Hospital
Pharmacies
• Retail
Pharmacies
• Others
Global Lysosomal Alpha Glucosidase Market Report by
Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment